Dr Gaia Schiavon


University departments
Department of Oncology
NHS or other affiliations
Late Oncology, Astrazeneca R&D

Position: Global Clinical Program Lead
Personal home page: https://uk.linkedin.com/in/gaia-schiavon-09604118

PubMed journal articles - click here

Research description

- Use of ctDNA analysis for early assessment of response / prediction of long term outcome, and to interrogate minimal residual disease
- Acquired therapy resistance mechanisms in ER positive breast cancers
- Novel biomarkers and study designs in ‘window of opportunity’ trials
- Identification of newer imaging criteria for response assessment to treatment of solid tumours to overcome RECIST’s limitations
- Pharmacodynamics in clinical trials, disease linkage data to guide indication selection and targeted patient populations

Research Programme or Virtual Institute
Breast Cancer Virtual Institute
Methods and technologies
Clinical trials
DNA sequencing
Tumour type interests
Uterus and unspecified

breast cancer AKT ctDNA ESR1 mutations early phase clinical trials

Key publications

* Equal contribution

- N. C. Turner, E. Alarcón, A. C. Armstrong, M Philco, Y. A. López Chuken, M. -P. Sablin, K. Tamura, A. Gómez Villanueva, J. A. Pérez-Fidalgo, S. Y. A. Cheung, C. Corcoran, M. Cullberg, B. R. Davies, E.C. de Bruin, A. Foxley, J. P. O. Lindemann, R. Maudsley, M. Moschetta, E. Outhwaite, M. Pass, P. Rugman, G. Schiavon and M. Oliveira. BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor AZD5363 capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Accepted by Ann Oncol
- Sarah Hrebien, Valentina Citi, Isaac Garcia-Murillas, Ros Cutts, Kerry Fenwick, Iwanka Kozarewa, Robert McEwen, Jayantha Ratnayake, Rhiannon Maudsley, Hedley Carr, Elza de Bruin, Gaia Schiavon, Nicholas Turner. Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial. Accepted by Ann Oncol
- Costanza Paoletti*, Gaia Schiavon*, Emily M. Dolce, Elizabeth P. Darga, T Hedley Carr, Joseph Geradts, Matthias Hoch, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Shethah Morgan, Parul Patel, Vicky Rowlands, Nitharsan Sathiyayogan, Kimberly Aung, Erika Hamilton, Manish Patel, Anne Armstrong, Komal Jhaveri, Seock-Ah Im, Nadia Iqbal, Fouziah Butt, Caroline Dive, Elizabeth A. Harrington, J Carl Barrett, Richard Baird, Daniel F. Hayes. Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD Phase I trial. Clin Cancer Res. 2018 Aug 6.
- Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nat Med. 2018 Jul 23.
- Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell GD, Acar A, Trahearn N, Hrebien S, Garcia-Murillas I, Chkhaidze K, Ermini L, Huntingford IS, Cottom H, Zabaglo L, Koelble K, Khalique S, Rusby JE, Muscara F, Dowsett M, Maley CC, Natrajan R, Yuan Y, Schiavon G, Turner N, Sottoriva A. The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. Clin Cancer Res. 2018 Jun 11.
- Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan SR, Schiavon G, Weir HM, Im SA. A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER(+)/HER2(-) Advanced Breast Cancer. Clin Cancer Res. 2018 Feb 13.
- Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumours and in PIK3CA-mutated breast and gynaecological cancers. Clin Cancer Res. 2018 May 1;24(9):2050-2059.
- Hyman DM*, Smyth LM*, Donoghue MTA, Westin S, Bedard P, Dean E, Bando H, El-Khoueiry A, Perez-Fidalgo J, Mita A, Schellens J, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai T, Torrisi J, Erinjeri, Ambrose H, Barrett J, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, and Taylor BS. AKT inhibition in solid tumors with AKT1 mutations. J Clin Oncol. 2017 Jul 10;35(20):2251-2259.
- Schiavon G, Hrebien S, Garcia-Murillas I, Pearson A, Tarazona N, Fenwick K, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin L-A, Dowsett M, Smith IE, Turner NC. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015 Nov 11;7(313):313ra182.
- Garcia-Murillas I*, Schiavon G*, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
- Barry PA, Schiavon G. Primary Systemic Treatment in the Management of Operable Breast Cancer: Best Surgical Approach for Diagnosis, Biological Evaluation, and Research. J Natl Cancer Inst Monogr. 2015 May;2015(51):4-8.
- Okada T*, Sinha S*, Esposito I*, Schiavon G, et al. Inactivation of the Rho-GTPase Rnd1 Induces Neoplastic Conversion and EMT by Activating Ras Signaling in Aggressive Subtypes of Breast Cancer. Nat Cell Biol 2015;17(1):81-94.
- Smith IE, Yeo B, Schiavon G. The Optimal Duration and Selection of Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Enough? Am Soc Clin Oncol Educ Book. 2014:e16-24.
- Schiavon G, Smith IE. Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Research 2014;16(2):206.
- Barry PA, Schiavon G, Macneill FA. Letter to the editor on 'Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial'. Ann Oncol. 2014 Apr;25(4):909-10.
- Schiavon G*, Ruggiero A*, Bekers DJ, et al. The effect of baseline morphology and it change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. Eur J Cancer. 2014 Mar;50(5):972-80.
- Smith IE, Schiavon G. Follow-up tests to detect recurrent disease: Patient's reassurance or medical need? Breast. 2013 Aug 1;22S2:S156-S160.
- Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer. Hematol Oncol Clin North Am. 2013 Aug;27(4):715-36, viii.
- Johnston SR, Schiavon G. Treatment algorithms for hormone receptor-positive advanced breast cancer. Am Soc Clin Oncol Educ Book. 2013:28-36.
- Schiavon G, Tait D, Briggs T and Smith IE. A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines. A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines. Clinical Breast Cancer. Clin Breast Cancer. 2013 Feb;13(1):77-80.
- Schiavon G, Ruggiero A, Schöffski P, et al. Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients. PLoS One. 2012;7(11):e48372.
- Daniele Santini, Bruno Vincenzi, Francesco M. Guida, Marco Imperatori, Gaia Schiavon, Olga Venditti, Anna M. Frezza, Pierpaolo Berti, Giuseppe Tonini. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012 Sep 17. pii: S1470-2045(12)70373-X.
- Schiavon G, Eechoute K, Sleijfer S, et al. Biliary excretion of imatinib and its active metabolite CGP74588 during severe liver dysfunction. J Clin Pharmacol. 2011
- Santini D*, Schiavon G*, Gaeta L, et al.. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast carcinomas. PLoS One. 2011 Apr 29;6(4):e19234.
- Li W, You L, Cooper J, Schiavon G, et al. Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus. Cell 2010